Fisetin’s grip-strength and frailty data in aged mice has led some in the fitness and biohacking community to ask whether it might also boost performance or recovery in younger, healthy, exercising people. The actual research answers a narrower and more specific question than that, and it’s worth being precise about what was tested and in whom.
Key Takeaways
- A 2025 Aging Cell study found intermittent fisetin dosing (1 week on, 2 weeks off, 1 week on) improved frailty and grip strength in old mice, comparable to genetic senescent-cell clearance and the synthetic senolytic ABT-263.
- Fisetin had no measurable effect on frailty or grip strength in young, healthy mice, supporting that it works through senescence-clearing mechanisms rather than as a general performance enhancer.
- At the molecular level, the improvements in old mice were accompanied by reduced expression of senescence-related genes in skeletal muscle tissue, including Cdkn1a and Ddit4.
- Human trials are underway, but in clinical populations, a pilot study is testing fisetin in people with peripheral artery disease (PAD), not in healthy athletes or exercisers.
What the 2025 Study Actually Tested
Researchers at the University of Colorado Boulder and the National Institute on Aging tested oral intermittent fisetin treatment, one week on, two weeks off, one week on, in old mice, measuring its effects on frailty and grip strength, and compared results directly against two established senolytic approaches: genetic clearance of senescent p16-positive cells, and treatment with the synthetic senolytic ABT-263[1]. Fisetin’s improvements in frailty and grip strength in old mice were comparable to both of these more invasive or pharmaceutical approaches, which is a meaningful result for a naturally derived flavonoid.
The Detail That Matters Most: No Effect in Young Mice
The same study also tested young, healthy mice for comparison, and found no comparable benefits from fisetin in that group[1]. This is the key finding for anyone hoping fisetin might work like a stimulant or performance enhancer: it didn’t improve frailty or grip strength measures in animals that weren’t already accumulating age-related senescent cell burden. The researchers explicitly frame this as support for the idea that fisetin works through senescence-related mechanisms specifically, not as a general muscle or performance booster that would help a young, healthy person train harder or recover faster.
What Happened at the Molecular Level
In the old mice that did respond, the functional improvements were accompanied by favorable changes in the skeletal muscle transcriptome, specifically lower expression of cellular senescence-related genes including Cdkn1a and Ddit4[1]. This gives the frailty and grip-strength results a plausible underlying mechanism rather than leaving them as an unexplained functional effect, and it reinforces that the benefit tracks with reducing senescent cell burden in aged muscle tissue specifically.
Where Human Research Stands
Human trials testing fisetin’s effects on muscle and physical function are underway, but they’re targeting clinical populations with elevated senescent cell burden, not athletes. A pilot trial (NCT06399809) is testing fisetin in people with peripheral artery disease, measuring senescent cell reduction in blood, skeletal muscle, and adipose tissue, alongside six-minute walk distance as a functional outcome[2]. Among the senolytic therapies currently in clinical trials, fisetin reportedly has the best safety profile of the three, which is part of why it’s being prioritized for this kind of trial, but this is still a study in a clinical population with vascular disease, not a study of exercise performance in healthy adults.
Practical Takeaway
If you’re an aging or frail adult, the mouse data on fisetin’s effects on grip strength and frailty is genuinely encouraging and mechanistically grounded, and the ongoing PAD trial will help clarify whether it translates to humans with senescence-related mobility limitations. If you’re a young, healthy person training and looking for a performance or recovery edge, the evidence base doesn’t support that use case: fisetin showed no benefit in young mice, and no human trial has tested it for athletic performance. Exercise itself, particularly high-intensity training, remains the better-evidenced intervention for muscle health in that population.
References
- Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. PMC12341784
- Fisetin to Reduce Senescence and Mobility Impairment in PAD. ClinicalTrials.gov NCT06399809
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
